BIOMAT Database Logo BIOMAT Database Logo

Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. 2001

M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada. crowthrm@fhs.csu.mcmaster.ca

To determine whether fibrinolytic testing predicts recurrent venous thrombosis, we have performed a prospective cohort study in which 303 patients with a first episode of venous thromboembolism underwent comprehensive fibrinolytic testing while receiving oral anticoagulants, and after anticoagulants had been discontinued. They were then followed for up to 3 years for recurrent venous thrombosis. No systematic differences in the levels or activity of type 1 plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (tPA) or euglobulin clot lysis times were detected between patients who did, or did not, suffer recurrent thrombosis. There were also no differences in these variables when patients whose initial thrombosis was idiopathic were compared to patients whose thrombosis occurred in the setting of a known thrombotic risk factor. Based on these results, neither measuring fibrinolytic parameters in patients with venous thromboembolism, nor modification of treatment based on the results of such testing, are justified. Our study also confirms that patients with idiopathic venous thromboembolism have a high risk of recurrence.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
January 2012, PloS one,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis.
March 1978, The American journal of medicine,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study.
November 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study.
March 2018, Thrombosis research,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Estimation of fibrinolytic activity of whole blood in patients with recurrent idiopathic deep venous thrombosis.
July 1986, Journal of vascular surgery,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.
October 2008, Journal of thrombosis and haemostasis : JTH,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study.
July 2017, The European respiratory journal,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Risk factors associated with recurrent venous thromboembolism after a first cerebral venous thrombosis event: A cohort study.
June 2019, Thrombosis research,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Incidence of deep venous thrombosis in patients undergoing elective neurosurgery - A prospective cohort based study.
January 2017, Neurology India,
M A Crowther, and J Roberts, and R Roberts, and M Johnston, and P Stevens, and P Skingley, and G M Patrassi, and M T Sartori, and J Hirsh, and P Prandoni, and J I Weitz, and M Gent, and J S Ginsberg
Factor XI and recurrent venous thrombosis: an observational cohort study.
May 2019, Journal of thrombosis and haemostasis : JTH,
Copied contents to your clipboard!